---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014559"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:54:51.642196+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RenovoRx closes $11.1M private placement; total 2024 raise $17.2M, funds Phase III trial into 2026

## Summary
- Gross proceeds of $11.1M from private placement of common stock, pre-funded, Series A, B, and placement agent warrants.
- Net proceeds estimated at ~$9.6M; total gross proceeds raised in 2024 now $17.2M from two placements.
- Issued 6,960,864 common shares, pre-funded warrant for 951,500 shares, Series A/B warrants for 7.9M and 3.96M shares.
- Proceeds for working capital, Phase III TIGeR-PaC trial in LAPC, and pipeline expansion into additional cancer indications.
- Company expects cash runway into 2026; second interim analysis for TIGeR-PaC estimated in late 2024.

## SEC filing metadata
- accession: 0001493152-24-014559
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/0001493152-24-014559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014559
- JSON: https://secwatch.observer/filing/0001493152-24-014559.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.